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1. Epidemiology and risk factors
Cholangiocarcinoma is a relatively rare primary malig-
nant neoplasia of the gallbladder (intra- and extrahepatic
bile ducts) with an incidence of 2−6 cases per 100,000 in
western countries. Over the last 20 years, an increase
in the incidence of intrahepatic and a decline in the
incidence of extrahepatic bile duct cancers has been
observed. Roughly, 10% of bile duct cancers are located
intrahepatically, 60% perihilar and 30% distal extrahep-
atically. The main risk factors for bile duct cancers
include: primary sclerosing cholangitis, ﬁbropolycystic
liver disease, cholelithiasis and, in some areas of the
world, parasitic infections.
2. Therapeutic options
Surgical resection is the only option for curative
therapy. However, the majority of patients present
with advanced disease at time of diagnosis. Other
established therapeutic options include: photodynamic
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endoscopic therapy for extrahepatic bile duct cancer,
external beam radiation therapy for selected cases,
and systemic chemotherapy. Combination chemotherapy
with gemcitabine and cisplatin has recently been
compared to gemcitabine alone in locally advanced
and metastatic cholangiocarcinoma in a large phase III
clinical trial. 1 Overall survival was 11.7 months in the
combination therapy arm compared to 8.1 months with
monotherapy. 1 Local transarterial therapies including
selective internal radiation therapy (SIRT) and trans-
arterial chemoembolisation (TACE) have so far only been
evaluated in small studies.
3. Evidence for SIRT
The evidence for SIRT in cholangiocarcinoma is based
on retrospective studies. Ibrahim et al. (2008) 2 treated
24 cholangiocarcinoma patients with yttrium-90 glass
microspheres; 29% of patients had previously received
chemotherapy, 80% had bilobar disease and 92% were
ECOG ‘0’ or ‘1’. Median survival was 9.3 months. Saxena
et al. (2010) 3 included 25 patients with cholangio-
carcinoma in a retrospective study with yttrium-90 resin
microspheres; 72% of patients had previously received
chemotherapy, 67% had bilobar disease, and 88% were
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ECOG ‘0’ or ‘1’. Median survival was 14.9 months. Hoff-
mann et al. (2012) 4 have recently published the largest se-
ries of SIRT, so far, in patients with cholangiocarcinoma.
Thirty-three patients were treated with yttrium-90 resin
microspheres and included in this analysis: 79% with
previous chemotherapy, 64% with bilobar disease, and
83% ECOG ‘0’ or ‘1’. Overall, 36.4% of patients had
partial remission, 51.5% had stable disease as best
response, resulting in a disease control rate of 85%.
Time to progression was 9.8 months, and median overall
survival was 22 months. Subgroup analysis revealed
that overall survival was best in patients with ECOG ‘0’
(29.4 months; 95%CI 17.7−44), those without previous
chemotherapy (22.7 months; 95%CI 5.1–22.7), those with
prior surgery for cholangiocarcinoma (26.7 months;
95%CI 5−44), and patients with a tumour burden25% of
the total liver volume (26.7 months; 95%CI 17.7–35.3).
Finally, Haug et al. (2011) 5 analysed the role of positron
emission tomography (PET) as an indicator for response
in a subgroup of patients from the Hoffmann study.
The analysis found that 18F-FDG PET independently
predicted survival in patients with cholangiocarcinoma
treated with SIRT.
4. Conclusions
Current evidence supports surgery, systemic chemo-
therapy, and photodynamic therapy as treatment options
for patients with cholangiocarcinoma. SIRT has so far
only been studied retrospectively. Especially patients
in a very good general condition, those with limited
disease, failure of prior surgery, and patients without
prior chemotherapy appear to beneﬁt best from SIRT.
Prospective clinical trials are needed to determine the
place of SIRT in the treatment algorithm for patients with
cholangiocarcinoma, either as a ﬁrst-line or as a salvage
therapy.
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